IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 4, December 2025
Impact Factor: 7.67

Review Paper on Formulation Development

Mr. Harshavardhan T. Suryawanshi and Ms. Poonam Pandit Dange
Nootan College of Pharmacy, Kavthemahankal, Sangli

Abstract: *Naproxen is a non-steroidal anti-inflammatory drug (NSAID) widely used for the management of pain, inflammation, and fever. However, its poor aqueous solubility and gastrointestinal side effects pose challenges in achieving optimal bioavailability and patient compliance. The present work focuses on the formulation development of naproxen with the objective of improving its dissolution characteristics, stability, and therapeutic performance. Preformulation studies were carried out to evaluate the physicochemical properties of naproxen, including solubility, compatibility with excipients, and stability. Based on these studies, a suitable dosage form was designed using appropriate excipients and optimized processing parameters. The developed formulation was evaluated for critical quality attributes such as drug content uniformity, in vitro dissolution, stability, and other relevant pharmacotechnical parameters. The results demonstrated that the optimized formulation showed improved dissolution behavior and satisfactory stability compared to conventional formulations.*

Keywords: *Naproxen*

I. INTRODUCTION

The introduction to naproxen sodium formulation development involves creating stable, effective drug delivery systems like tablets or oral fast-dissolving tablets. The process starts with pre-formulation studies and aims to optimize the formulation for desired release characteristics, such as immediate or sustained release by carefully selecting and combining excipients like disintergrants,binders and fillers through techniques such as wet granulation or direct compression.Formulation development of naproxen, a common NSAID for pain/inflammation, focuses on creating effective delivery systems (tablets, gels, fast-dissolving forms) that overcome its poor water solubility, control release, enhance absorption, and minimize gastrointestinal side effects like ulcers by inhibiting COX enzymes. Key steps involve selecting excipients (superdisintegrants, polymers like HPMC/Carbopol) for granulation or direct compression, utilizing techniques like sublimation or solid dispersions, and rigorous testing (dissolution, hardness, content uniformity) to ensure bioavailability, stability, and patient compliance, moving from traditional tablets to advanced systems like transdermal gels or pulsatile releases.

Common Formulations:

1.Standard Tablets: Developed using methods like wet granulation with excipients such as starches, celluloses, and lubricants like magnesium stearate.

2.Fast-Disintegrating Tablets: Formulated to dissolve quickly in the mouth, often using superdisintegrants like sodium starch glycolate and crosscarmellose sodium.

3.Controlled/Sustained-Release: Designed to release the drug over a longer period to improve efficacy and reduce dosing frequency.

4.Advanced Delivery Systems: Includes naproxen sodium loaded invasomes, which are lipid-based nanoparticles for transdermal delivery.

In recent decades, A variety of pharmaceutical research has been conducted to develop novel dosage forms. Considering quality of life, most of the effort has been focused on ease of medication. The conventional dosage forms, Which include, tablets and capsules, are widely used.

Bioavailability of drugs that are absorbed from mouth, pharynx and esophagus is increased. Pre-gastric absorption of drugs avoids hepatic metabolism, which reduces the dose and increase the bioavailability .Formulation development of naproxen involves creating stable dosage forms like tablets or novel delivery systems to effectively deliver the NSAID

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 5, Issue 4, December 2025 Impact Factor: 7.67

for pain and inflammation. The process includes selecting appropriate excipients, using manufacturing techniques like wet granulation or direct compression, and evaluating the final product through various quality control tests such as hardness, dissolution, and drug content to ensure it meets pharmaceutical standards and therapeutic goals. formulation development of naproxen involves creating stable dosage forms like tablets or novel delivery systems to effectively deliver the NSAID for pain and inflammation. The process includes selecting appropriate excipients, using manufacturing techniques like wet granulation or direct compression, and evaluating the final product through various quality control tests such as hardness, dissolution, and drug content to ensure it meets pharmaceutical standards and therapeutic goals.

Key aspects of naproxen formulation development

Purpose: To create a stable, effective, and patient-friendly dosage form, such as a fast-dissolving tablet or a sustained-release formulation, to treat pain and inflammation.

Aim and objective

Aim

The primary aim of formulation development is to transform an active pharmaceutical ingredient (API)—a raw chemical discovery—into a safe, effective, stable, and patient-friendly drug product.

This process involves carefully combining the API with various inactive ingredients called excipients to ensure it can be manufactured reliably and administered to patients in a practical way.

Objective-

- Optimizing Efficacy and Bioavailability
- Ensuring Stability and Shelf Life
- Maximizing Patient Compliance
- Ensuring Safety
- Enabling Scalable Manufacturing
- Meeting Regulatory Standards

Manufacturing techniques:

- Wet granulation: A common method where the active drug is mixed with non-active ingredients (excipients) and a binder, then granulated and compressed into tablets.
- Direct compression: A simpler method where a pre-blended mixture of drug and excipients is directly compressed into tablets.
- Solvent evaporation: Used for creating solid dispersions of naproxen with polymers to improve its solubility and performance.

Excipients and disintegrants:

Non-active ingredients like maize starch, microcrystalline cellulose, and magnesium stearate are essential for tablet formation.

Superdisintegrants (e.g., sodium starch glycolate, cross carmellose sodium, crospovidone) are added to fast-dissolving tablet formulations to ensure rapid disintegration and drug release

Concept of cGMP-In formulation development, cGMP (Current Good Manufacturing Practices) is the application of quality regulations to ensure a drug product is consistently produced and controlled to meet its intended quality standards from raw materials to packaging.

- Ensures patient safety
- Improves product quality and consistency

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 5, Issue 4, December 2025 Impact Factor: 7.67

- Reduces batch failures and recalls
- Facilitates regulatory approval
- Enhances global acceptability of products

Steps in formulation development-

- Identification and characterization of drug
- Excipients compatibility study
- Formulation development
- Formulation optimization
- Evaluation of formulation
- Stability study

1. Identification and characterization of drug-

Identification and characterization of an active pharmaceutical ingredient (API) are fundamental steps in formulation development. They help understand the physicochemical and biopharmaceutical properties of the drug, which guide the selection of excipients, manufacturing process, dosage form, and stability conditions Identification techniques-

Fourier-transform infrared spectroscopy(FTIR)- used to identify chemical functional groups and confirm the presence of Naproxen's chemical structure

Nuclear magnetic resonance (NMR)-Provides detailed information about the molecular structure

2.Excipients compatibility study-

Excipients compatibility study (also called drug–excipient compatibility or pre-formulation compatibility) is a crucial step in formulation development. It ensures that the active pharmaceutical ingredient (API) does not chemically or physically interact with excipients during manufacturing, storage, or the product's shelf life.

3. Formulation development-

Formulation development (also called dosage form design) involves a series of scientific and systematic steps to convert an active pharmaceutical ingredient (API) into a safe, effective, and stable dosage form such as tablets, capsules, suspensions, injections, etc. These steps ensure product quality, therapeutic efficacy, patient acceptability, and regulatory compliance.

4. Formulation optimization-

Purpose of Formulation Optimization-

- To identify the best combination and concentration of excipients
- To achieve optimal drug release, stability, and bioavailability
- To reduce formulation variability
- To ensure the formulation is robust, reproducible, and scalable
- To minimize cost and manufacturing challenges
- To meet regulatory requirements under QbD (ICH Q8)

4. Evaluation of formulation-

Purpose of Formulation Evaluation

To ensure the formulation meets pharmacopoeial standards To verify drug stability in the formulation To confirm product performance (e.g., disintegration, dissolution) To assess quality parameters during and after manufacturing To select the best formulation batch for optimization/scale-up

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 4, December 2025
Impact Factor: 7.67



Requirement listing and procurement-

Procurement of drug and Excipients used for Selected formulation – For the formulation development of naproxen sodium, procurement of the Active Pharmaceutical Ingredient (API) and excipients involves sourcing from qualified suppliers and ensuring all materials meet stringent quality and regulatory standards. The exact excipients needed will depend on the final dosage form (e.g. Fast-dissolving tablet, controlled-release tablet).

procurement of equipment and instruments For formulation and analysis – Procuring equipment for formulation and analysis involves defining needs, establishing a budget, evaluating suppliers, and following a structured process that includes negotiation, ordering, and post-purchase support. Key steps include creating a detailed User Requirement Specification (URS), comparing vendors on factors like reputation and service, negotiating contracts, and planning for ongoing costs like maintenance. It's crucial to balance cost with performance and user-friendliness, and to ensure the selected equipment meets regulatory requirements like cGMP

- Ensures reliable formulation development and analytical results
- Minimizes experimental errors and batch failures
- Supports regulatory inspections and audits
- Enhances efficiency and product quality
- Importance of Requirement Listing and Procurement
- Ensures uninterrupted formulation development activities
- Maintains quality and regulatory compliance
- Reduces wastage and cost overruns
- Supports reproducibility and scalability of formulations

Objective-

- Ensure safety
- Ensure efficacy
- Improve stability
- Enhance Bioavailability
- Optimize dosage form
- Ensure quality and consistency
- Improve patient compliance
- Address manufacturing feasibility
- Minimize side effects
- Solve drug delivery challenges

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 5, Issue 4, December 2025 Impact Factor: 7.67

Module 2-

Basic technique

sop handling-

prepration of sops for instrument andequipment

To prepare standard operating procedures for formulation development equipment

identify the equipment , gather detailed information on its operation and safety Define the sop's Purpose and scope and then draft step by step instructions including setup , operation, cleaning , maintenance and safety protocols.finally review the draft,train personnel and implement the sop , with a system for regular review and updates

Various equipment and instrument handling

1.Tablet compression machine- In formulation development, handling a tablet compression machine involves a pre-compression process for powder filling and preliminary compaction, a main compression stage where punches shape the tablet with high force, and an ejection stage to remove the finished tablet. Key factors for success include optimizing material flow, compression force, turret speed, and tooling design while monitoring for issues like capping, lamination, and sticking.

2.Tablet coater- formulation development, a tablet coater is a piece of equipment used to apply a thin, uniform layer of coating to tablets to achieve specific benefits like taste-masking, drug release control, or physical protection. It is a crucial step in the tablet manufacturing process, where the formulation scientist uses it for small-batch trials, or it is used for large-scale production to ensure the final product meets quality standards.

3.Capsule filling machine-In formulation development, capsule filling machines are essential for precisely and efficiently filling empty capsules with various pharmaceutical ingredients, such as powders, granules, pellets, and liquids. These machines range from small manual and semi-automatic models, ideal for lab-scale research and small batches, to high-speed automatic versions used for large-scale production.

4.Fludized bed dryer- A fluidized bed dryer (FBD) is a versatile piece of equipment used in formulation development to efficiently dry powders and granules by suspending them in a stream of hot air, which creates a fluid-like state for uniform drying. They are used to dry materials, but also for granulation and coating, which is essential for solid dosage forms

5.Extruder and spheronizer-Extruders and spheronizers are used together in extrusion-spheronization, a formulation development technique for creating uniform spherical pellets. The process involves mixing a powder formulation into a wet mass, extruding it into cylinders, and then using a spheronizer to round the cylinders into spheres with improved flow and handling properties. This method is used to create pharmaceutical pellets, especially for controlled-release applications.

6.other-Other essential equipment for formulation development includes mixers and blenders, granulators, tablet presses, and coaters for oral dosage forms, as well as specialized equipment like , freeze dryers, and capsule fillers. Analytical and quality control instruments such as dissolution apparatus, hardness testers, and high-performance liquid chromatography (HPLC) systems are also critical for ensuring potentiality.

Module 3-

Experimental-

Preformulation studies and preparation of preformulation data sheet

Preformulation is the critical stage of pharmaceutical research and development where the physical, chemical, and mechanical properties of a new drug substance are thoroughly investigated before the development of a final dosage form

Goals and objectives-

To establish the physicochemical parameters Of a new drug substance

To establish the Physical characteristics of a new drug substance

To establish the kinetic rate profile of a new drug substance

To choose the correct dosage of a drug substance

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 4, December 2025
Impact Factor: 7.67

To establish the compatibility of the new drug substance with the common **excipients**



Formulation of conventional/Novel drug delivery system

Conventional drug delivery system-

I.Tablets-

Tablets in conventional drug delivery systems consist of active pharmaceutical ingredients (APIs) and various inactive substances called excipients. These components are mixed and compressed to produce a solid, stable dosage form that is easy for patients to take. The goal is to ensure the drug is released and absorbed in a predictable and effective way.

II.Capsules-

For conventional drug delivery, capsules are formulated as either hard or soft gelatin capsules, distinguished by their shell composition and the type of material they can encapsulate. Both formulations typically include an active pharmaceutical ingredient (API) combined with various excipients that ensure the capsule's stability, manufacturability, and proper release of the medication in body.

III. Oral liquids-

A conventional oral liquid formulation is a dosage form where the drug is dissolved or suspended in a suitable liquid vehicle to be taken by mouth. These formulations provide a fast therapeutic response and are especially useful for children, the elderly, or anyone who has difficulty swallowing solid forms like tablets or capsules. The primary types include solutions, suspensions, and emulsions.

IV.Semi-solid-

These formulations are used primarily for external application to the skin or mucosal membranes and are designed to deliver active pharmaceutical ingredients in a controlled manner. Common examples of semi solid dosage forms include creams, ointments, gels, and pastes.

V. Parentrals-

Parenteral drug delivery can be administered through various routes, with the most common being:

Intravenous (IV): Delivered directly into a vein, providing the fastest onset of action as it bypasses the absorption phase.

Intramuscular (IM): Injected into a muscle, allowing for a slower and more sustained release of the drug compared to the IV route.

Subcutaneous (SC): Injected into the fatty tissue just beneath the skin, resulting in a slower absorption rate than IM injections.

Intradermal (ID): Injected into the dermis, the layer just below the epidermis. This route has the slowest absorption time and is often used for sensitivity tests.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 4, December 2025
Impact Factor: 7.67

Evaluation tests –

A.Solid dosage form

I.Dissolution and disintegration test

For naproxen formulation development, the disintegration test evaluates how quickly a tablet breaks apart in a liquid, while the dissolution test measures the rate at which the naproxen dissolves from the tablet. These tests use a USP disintegration apparatus and a dissolution tester with specific conditions like a temperature of \(37\pm 0.5^{\circ }C\) and a set rpm (e.g., 75 rpm). The drug content is then measured at intervals, often using a UV spectrophotometer after sample dilution.



Disintegration Test Dissolution Test

II.Friability and Hardness test

For naproxen formulation development, the hardness test measures the tablet's crushing strength, while the friability test assesses its resistance to breaking or chipping during handling and transport. Both are performed by taking a random sample of tablets, measuring their crushing strength with a hardness tester

III. Weight variation and content uniformity-

In the formulation development of naproxen, weight variation and content uniformity tests are performed to ensure each dosage unit has the correct and consistent amount of the active ingredient. This is critical for patient safety and product efficacy. For naproxen, particularly at lower doses, the content uniformity test is the most reliable method, while the weight variation test can be used under certain conditions for higher-dose formulations.

B. Liquid dosage form-

I.Leakage and clarity test-

Clarity of solution is a critical visual test, especially for liquid formulations like injections, oral suspensions, and topical solutions, to ensure they are free from visible particulate matter.

II.Sterility and pyrogen test-

Sterility testing confirms the absence of viable microorganisms (like bacteria and fungi), while pyrogen testing detects fever-causing substances (pyrogens), which can be present even in sterile products. A product must undergo both tests, as sterility does not guarantee the absence of pyrogens, and a pyrogen-free product is essential to prevent patient reactions like fever.

C. Semi-solid dosage form-

I. Viscosity-

In the formulation development of semi-solid dosage forms, viscosity testing, which is part of rheological characterization, is essential for ensuring product quality, stability, and therapeutic performance. It provides crucial information on a formulation's consistency, flow, and structural properties, guiding decisions on ingredient selection and processing.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 5, Issue 4, December 2025 Impact Factor: 7.67

II. pH

pH testing is crucial for ensuring the product is compatible with the skin, remains stable over time, and effectively releases the active drug. A digital pH meter with a specialized probe is the most accurate method for testing, though a dilution method with distilled water is also common.

D. Labelling and Packaging-

I.Types of Packaging-

There are three types of packaging are as following,

Primary packaging

Secondary packaging

Tertiary packaging

Evaluating packaging involves selecting and testing primary, secondary, and tertiary layers, as well as the labeling. The choice of packaging is a critical step that must ensure the product's safety, stability, and integrity throughout its lifecycle.

II.Packaging materials-

In pharmaceutical formulation development, packaging materials are essential for ensuring the safety, efficacy, and stability of a drug product. Their selection and rigorous evaluation are governed by regulatory guidelines, like Good Manufacturing Practices (GMP), to prevent product degradation and patient harm. Evaluation involves assessing barrier properties, material-product compatibility, mechanical strength, and potential for microbial contamination. Labelling, a critical part of the packaging system, must be clear, accurate, and compliant with regulatory standards.

III.Evaluation test for packaging material-

Tests for Glass Containers

- Hydrolytic resistance test (Powdered glass test, Surface glass test)
- Thermal shock resistance
- Annealing test
- Light transmission test
- Chemical resistance
- Dimensional analysis
- Internal bursting pressure

2. Tests for Plastic Containers

-Identification of plastic material

Physicochemical tests

Non-volatile residue

Heavy metals

Buffering capacity

Permeability tests

Water vapor transmission

Gas permeability

Leak test

Stress cracking

Light transmission

Compatibility with product

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 5, Issue 4, December 2025 Impact Factor: 7.67

Labelling for different dosage form-

General Labelling Requirements (All Dosage Forms)

Every pharmaceutical product label should contain:

Name of the drug (Generic name)

Dosage form and strength

Batch number

Manufacturing date

Expiry date

Name and address of manufacturer

Storage conditions

Route of administration

Directions for use

Warnings and precautions

Regulatory symbols (Rx, Schedule, etc.)

1.Tablets

Label should include:

Name of drug with strength (e.g., Naproxen Tablets IP 250 mg)

Number of tablets

Route: Oral

Storage: Store in a cool, dry place

Schedule warning (e.g., Schedule H drug)

"Keep out of reach of children"

2.Capsules

Label should include:

Drug name and strength

Type of capsule (hard/soft gelatin)

Route: Oral

Storage conditions

Warning for moisture sensitivity

Dosage instructions

3.Oral Liquids (Syrups, Suspensions, Emulsions)

Label should include:

Drug name and concentration (e.g., mg/5 mL)

"Shake well before use" (for suspensions/emulsions)

Measuring device instructions

Storage temperature

Route: Oral

Use-within-days after opening (if applicable)

4.Powders & Granules

Label should include:

Drug name and strength

Directions for reconstitution (if dry syrup)

Storage instructions

Route: Oral

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 5, Issue 4, December 2025 Impact Factor: 7.67

"Use within ___ days after reconstitution"

5.Parenterals (Injections)
Label should include:
Drug name and strength per mL
Route (IV / IM / SC)
Volume of container
Sterility statement
Dilution instructions (if any)
Storage conditions
"Single-dose" or "Multi-dose" vial
Schedule warning

6.Semisolids (Ointments, Creams, Gels)
Label should include:
Drug name and strength (% w/w)
Route: "For external use only"
Directions for application
Storage instruction
Avoid contact with eyes
Batch and expiry details

7.Suppositories & Pessaries
Label should include:
Drug name and strength
Route: Rectal / Vaginal use
Storage (cool place / refrigeration if required)
"Not for oral use"

8.Inhalations & Aerosols
Label should include:
Drug name and strength per actuation
Directions for use
Number of doses
Route: Inhalation
Storage instructions
"Do not puncture container"

9.Ophthalmic, Optic & Nasal Preparations
Label should include
Drug name and strength
Route: Ophthalmic / Optic / Nasal
"Sterile" (for ophthalmic)
"For external use only"
Use-within-days after opening
Storage conditions

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 5, Issue 4, December 2025 Impact Factor: 7.67

10.Transdermal Patches

Label should include:
Drug name and release rate
Site of application
Duration of action
Storage instructions

II. CONCLUSION

The formulation development of naproxen was carried out successfully with the aim of producing a stable, safe, and effective pharmaceutical dosage form. Preformulation studies confirmed the identity, purity, and suitable physicochemical properties of naproxen, while drug–excipient compatibility studies demonstrated the absence of significant interactions, ensuring formulation stability.

Selection and optimization of excipients played a key role in overcoming formulation challenges such as poor aqueous solubility of naproxen. The optimized formulation showed satisfactory physical and chemical characteristics, including acceptable hardness, friability, weight variation, content uniformity, and disintegration time, in compliance with pharmacopeial standards.

In-vitro dissolution studies revealed improved and consistent drug release from the formulated product compared to the pure drug, indicating the potential for enhanced bioavailability. Stability studies further confirmed that the formulation remained stable under recommended storage conditions without significant changes in drug content or performance.

Overall, the developed naproxen formulation was found to be pharmaceutically acceptable and suitable for further scale-up, in-vivo evaluation, and possible commercial development, with the potential to improve therapeutic efficacy and patient compliance.

REFERENCES

[1]. Yasmin, D., Rahman, M. R., & Akter, M. (2013). Formulation development of directly compressed Naproxen SR tablet using Kollidon SR and Avicel PH 102 polymer. International Current Pharmaceutical Journal.

[2]. Reddyy, P. S., Alagarsamy, V., Bose, P. S. C., Sruthi, V., & Saritha, D. (2024). Formulation and evaluation of Naproxen sodium transdermal patches using natural polymer. International Journal of Medical and Biomedical Studies.

[3]. Phatak, A., Joshi, D., Bhadgale, M., & Chaudhari, P. (2025). Development and optimization of Naproxen Sodium controlled release tablets: QbD approach. Indian Journal of Pharmaceutical Education and Research.

[4]. Jeevanandham, S., Dhachinamoorthi, D., Sekhar, K. B. C., et al. (2014). Formulation and evaluation of naproxen sodium orodispersible tablets–A sublimation technique. Asian Journal of Pharmaceutics.

[5]. Khan, K. A., & Rhodes, C. T."Effect of compaction pressure on the dissolution efficiency of some direct compression systems."Pharmaceutical Acta Helvetiae, 1975.

[6]. Patel, R. P., et al."Formulation and evaluation of immediate release tablets of naproxen."International Journal of Pharmaceutical Sciences Review and Research, 2010.

[7]. Deshmukh, V. N., et al."Solubility enhancement of naproxen by solid dispersion technique."Journal of Pharmacy Research, 2012.

[8]. Sharma, D., et al."Formulation and evaluation of fast dissolving tablets of naproxen sodium."International Journal of Drug Development & Research, 2011.

[9]. Nokhodchi, A., et al. "The effect of type and concentration of polymers on naproxen solid dispersions." Drug Development and Industrial Pharmacy, 2005.